Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Active zone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    81 result(s) found for: Active zone. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2009-011725-14 Sponsor Protocol Number: IELSG 34 Start Date*: 2010-06-23
    Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)
    Full Title: IELSG 34: A Multicenter Phase II study to evaluate the clinical activity and the safety profile of everolimus (RAD001) in marginal zone B-cell lymphomas (MZL) EudraCT Number 2009-011725-14
    Medical condition: Relapsed or refractory marginal zone B-cell lymphomas.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029463 LLT
    9.1 10041652 LLT
    9.1 10015823 LLT
    9.1 10015824 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001768-31 Sponsor Protocol Number: ZENO-01 Start Date*: 2012-09-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma)
    Medical condition: MALT Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004289-42 Sponsor Protocol Number: ZENO-06021957 Start Date*: 2008-03-20
    Sponsor Name:National and Kapodistrian University of Athens
    Full Title: 90Y ibritumomab tiuxetan (Zevalin®) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma)
    Medical condition: extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000970-12 Sponsor Protocol Number: INCB50465-204 Start Date*: 2017-10-13
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor.
    Medical condition: Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) BE (Completed) DK (Completed) FR (Ongoing) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001591-80 Sponsor Protocol Number: INFL08 Start Date*: 2008-05-12
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: PHASE II STUDY OF LENALIDOMIDE IN COMBINATION WITH RITUXIMAB (R) FOR THE TREATMENT OF INDOLENT NON FOLLICULAR NON HODGKIN LYMPHOMA
    Medical condition: Histological proved diagnosis of B-cell CD20-positive non follicular NHL according to REAL/WHO Classification: a. small lymphocytic lymphoma b. lymphoplasmacytic lymphoma/Waldenstrom macroglobul...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029463 LLT
    9.1 10003911 LLT
    9.1 10041652 LLT
    9.1 10025345 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012703-25 Sponsor Protocol Number: PHSU02 Start Date*: 2009-11-03
    Sponsor Name:Pergamum AB
    Full Title: A prospective double-blind, randomised concept study of PXL01 versus placebo in flexor tendon surgery.
    Medical condition: Patients with flexor tendon injuries in zone I or II that are admitted to the respective site will be considered for inclusion and informed about the study.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10043248 Tendon rupture PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002117-28 Sponsor Protocol Number: ACE-LY-004 Start Date*: 2015-05-06
    Sponsor Name:Acerta Pharma B.V.
    Full Title: An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005702-22 Sponsor Protocol Number: IELSG39 Start Date*: 2013-03-17
    Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP
    Full Title: International prospective Phase 2 trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycycline followed by eradication moni...
    Medical condition: Patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004158-17 Sponsor Protocol Number: GELTAMO-IMCL-2015 Start Date*: 2016-02-15
    Sponsor Name:GELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea)
    Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma.
    Medical condition: Mantle Cell Lyphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003893-17 Sponsor Protocol Number: SAKK36/13 Start Date*: 2017-11-23
    Sponsor Name:SAKK, Swiss Group for Clinical Cancer Research
    Full Title: Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial
    Medical condition: Histologically confirmed mantle cell lymphoma in need of systemic treatment Refractory or relapsed disease after pretreatment of non-bortezomib containing chemotherapy including high-dose therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026800 Mantle cell lymphoma recurrent PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002236-91 Sponsor Protocol Number: AOIGCSMerri/2018/PS-01 Start Date*: 2019-12-18
    Sponsor Name:CHU de Nîmes
    Full Title: Place des inhibiteurs de la transcriptase inverse dans le traitement du psoriasis : Essai « preuve de concept biologique »
    Medical condition: Les patients âgés de 18 à 70 ans atteints de psoriasis en plaques depuis plus d’un an avec présence d’au moins une lésion cutanée active > à 4 cm2 en zone photo-protégée se verront proposer de part...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002935-30 Sponsor Protocol Number: 20-01434 Start Date*: 2023-01-20
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphom...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000540-25 Sponsor Protocol Number: FIL_KLIMT Start Date*: 2019-06-25
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D) for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas: a phase II study
    Medical condition: BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000111-84 Sponsor Protocol Number: ACE-LY-003 Start Date*: 2020-02-04
    Sponsor Name:ACERTA PHARMA BV
    Full Title: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma
    Medical condition: B-cell Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003579-22 Sponsor Protocol Number: MO39107 Start Date*: 2017-08-02
    Sponsor Name:Roche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann- La Roche
    Full Title: A PHASE II STUDY EXPLORING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB ADMINISTERED IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB ANTI-CD20 THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMP...
    Medical condition: Relapsed/Refractory Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054697 Waldenstrom's macroglobulinemia recurrent LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054698 Waldenstrom's macroglobulinemia refractory LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077534 Marginal zone lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077533 Marginal zone lymphoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026800 Mantle cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) LV (Completed) GR (Completed) SK (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003041-10 Sponsor Protocol Number: CRFB002H2301 Start Date*: 2015-04-14
    Sponsor Name:NOVARTIS FARMA S.p.A.
    Full Title: RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of prematu...
    Medical condition: Retinopathy of prematurity (ROP)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) EE (Completed) LT (Completed) HU (Completed) BE (Completed) AT (Completed) DE (Completed) GB (Completed) HR (Completed) FR (Completed) SK (Completed) CZ (Completed) GR (Completed) DK (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002602-52 Sponsor Protocol Number: BAY80-6946/16349 Start Date*: 2012-10-19
    Sponsor Name:Bayer AG
    Full Title: Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas
    Medical condition: Patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas or patients with follicular lymphoma relapsed after or refractory to standard therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    20.0 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    20.0 100000004851 10029608 Non-Hodgkin's lymphomas unspecified histology aggressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) SE (Completed) PL (Completed) AT (Completed) PT (Completed) HU (Completed) DK (Prematurely Ended) IE (Completed) GR (Completed) LU (Completed)
    Trial results: View results
    EudraCT Number: 2018-002611-99 Sponsor Protocol Number: 20090 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer AG
    Full Title: Open-label, randomized, two–arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy ...
    Medical condition: Retinopathy of prematurity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) NL (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) SK (Completed) AT (Completed) BG (Completed) PL (Completed) ES (Completed) HU (Completed) LT (Completed) EE (Completed) LV (Completed) GR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003148-19 Sponsor Protocol Number: INCB50465-205 Start Date*: 2018-05-15
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor.
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001850-80 Sponsor Protocol Number: NLG-MCL8 Start Date*: 2021-04-07
    Sponsor Name:Skåne University Hospital
    Full Title: Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma
    Medical condition: Mantle Cell Lymphoma (MCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 13:29:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA